Cargando…
Lipid-lowering therapy: who can benefit?
Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still causes one in every six deaths in this country. Because most CHD risk factors are modifiable (eg, smoking, hypertension, obe...
Autor principal: | Lewis, Sandra J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166192/ https://www.ncbi.nlm.nih.gov/pubmed/21915170 http://dx.doi.org/10.2147/VHRM.S23113 |
Ejemplares similares
-
Persistence With Lipid-Lowering Therapy: Influence of the Type of Lipid-Lowering Agent and Drug Benefit Plan Option in Elderly Patients
por: Abughosh, Susan M., et al.
Publicado: (2004) -
The Future of Lipid-Lowering Therapy
por: van Zwol, Willemien, et al.
Publicado: (2019) -
Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
por: Khan, Irfan, et al.
Publicado: (2020) -
Targeted Strategy in Lipid-Lowering Therapy
por: Dayar, Ezgi, et al.
Publicado: (2022) -
Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?
por: Arnold, Natalie, et al.
Publicado: (2020)